Skip to content
10-Q

Quarterly Report

Akebia Therapeutics, Inc. AKBA

0001628280-25-023460

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 262.64M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $46.51M
Long Term Debt Q1 2025 · Dec 31, 2024 $38.69M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $113.37M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $51.87M
Current Liabilities Q1 2025 · Mar 31, 2025 $91.23M
Current Liabilities Q1 2025 · Dec 31, 2024 $80.91M
Total Liabilities Q1 2025 · Mar 31, 2025 $285.6M
Total Liabilities Q1 2025 · Dec 31, 2024 $269.86M
Current Assets Q1 2025 · Mar 31, 2025 $203.78M
Current Assets Q1 2025 · Dec 31, 2024 $113.83M
Total Assets Q1 2025 · Mar 31, 2025 $310.19M
Total Assets Q1 2025 · Dec 31, 2024 $220.67M
Shares Diluted Q1 2025 · Mar 31, 2024 204.96M sh
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.43M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$27.26M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$30.58M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.09
Eps Basic Q1 2025 · Mar 31, 2024 −$0.09
Sga Expense Q1 2025 · Mar 31, 2024 $25.44M
Rd Expense Q1 2025 · Mar 31, 2024 $9.73M
Net Income Q1 2025 · Mar 31, 2024 −$17.99M
Operating Income Q1 2025 · Mar 31, 2024 −$14.94M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $11.61M
Revenue Q1 2025 · Mar 31, 2024 $32.61M